One step closer to imaging vulnerable plaque in the coronary arteries

Journal of Nuclear Medicine

Volumn 50, Issue 4, 2009, Pages 497-500

  Fox, Josef J ^a   Strauss, H William ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; FATTY ACID; FLUORODEOXYGLUCOSE F 18; LEVOTHYROXINE; ROSIGLITAZONE; SIMVASTATIN; TRIMETAZIDINE;

ATHEROMA; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CELL METABOLISM; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG TUMOR LEVEL; DRUG UPTAKE; GLUCOSE INTAKE; GLUCOSE OXIDATION; HEART MUSCLE CELL; HUMAN; LIPID PEROXIDATION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CORONARY ARTERY DISEASE; CORONARY VESSELS; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 63849262815     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.056325     Document Type: Review

References (45)

1. American Heart Association. Statistics. Available at: http://www.americanheart.org/presenter.jhtml? identifier=1200026. Accessed February 17, 2009.
2. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985;53:363-373.
3. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47(8, suppl):C13-C18.
4. Spagnoli LG, Bonanno E, Sangiorgi G, Mauriello A. Role of inflammation in atherosclerosis. J Nucl Med. 2007;48:1800-1815.
5. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670-675.
6. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeox-yglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301-1306.
7. Vallabhajosula S, Fuster V. Atherosclerosis: imaging techniques and the evolving role of nuclear medicine. J Nucl Med. 1997;38:1788-1796.
8. 18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708-2711.
9. 18F- fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818-1824.
10. 18Fluorode-oxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892-896.
11. Ben-Haim S, Kupzov E, Tamir A, Frenkel A, Israel O. Changing patterns of abnormal vascular wall F-18 fluorodeoxyglucose uptake on follow-up PET/
12. CT studies. J Nucl Cardiol. 2006;13:791-800.
13. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825-1831.
14. 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med.2008;49:1277-1282.
15. 18F-FDG uptake with vascular calcification. J Nucl Med. 2005;46:1278-1284.
16. 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009;50:563-568.
17. Herrero P, Gropler RJ. Imaging of myocardial metabolism. J Nucl Cardiol. 2005;12:345-358.
18. Bing RJ, Fenton JC. Cardiac metabolism. Annu Rev Med. 1965;16:1-2.
19. Stanley WCLG, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc Res. 1997;33:243-257.
20. Fukuchi K, Ohta H, Matsumura K, Ishida Y. Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies. Br J Radiol. 2007;80:3-11.
21. de Groot M, Meeuwis AP, Kok PJ, Corstens FH, Oyen WJ. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging. 2005;32:98-101.
22. Kaneta T, Hakamatsuka T, Takanami K, et al. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization. Ann Nucl Med. 2006;20:203-208.
23. Gropler RJ, Siegel BA, Lee KJ, et al. Non-uniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med. 1990;31:1749-1756.
24. Schwaiger M, Hicks R. Regional heterogeneity of cardiac substrate metabolism? J Nucl Med. 1990;31:1757-1760.
25. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61-77.
26. 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR. 2008;190: W151-W156.
27. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785-789.
28. Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care. 2007;10:142-148.
29. Frayn KN. The glucose-fatty acid cycle: a physiological perspective. Biochem Soc Trans. 2003;31:1115-1119.
30. 18F]2-fluoro-2-deoxyglucose for the measure of myocardial glucose metabolism. J Nucl Med. 1978;19:1311-1319.
31. Bax JJ, Veening MA, Visser FC, et al. Optimal metabolic conditions during fluorine-18 fluorodeox-yglucose imaging: a comparative study using different protocols. Eur J Nucl Med. 1997;24:35-41.
32. Taegtmeyer H, King LM, Jones BE. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. Am J Cardiol. 1998;82:54K-60K.
33. Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardio-myopathy. Circulation. 2008;118:1250-1258.
34. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99:578-588.
35. Hallsten K, Virtanen KA, Lonnqvist F, et al. Enhancement of insulin-stimulated myocardial glucose uptake in patients with type 2 diabetes treated with rosiglitazone. Diabet Med. 2004;21:1280-1287.
36. 18F-FDG uptake. J Nucl Med. 2007; 48:234-239.
37. Sugden MC, Holness MJ, Liu YL, Smith DM, Fryer LG, Kruszynska YT. Mechanisms regulating cardiac fuel selection in hyperthyroidism. Biochem J. 1992;286:513-517.
38. Nuutinen J, Minn H, Bergman J, et al. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study. Br J Cancer. 1999;80:513-518.
39. Higashida T, Kanno H, Nakano M, Funakoshi K, Yamamoto I. Expression of hypoxia-inducible angiogenic proteins (hypoxia-inducible factor-1α, vascular endothelial growth factor, and E26 transformation-specific-1) and plaque hemorrhage in human carotid atherosclerosis. J Neurosurg. 2008;109:83-91.
40. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol. 2002;15:439-446.
41. Otsuka M, Bruining N, Van Pelt NC, et al. Quantification of coronary plaque by 64-slice computed tomography: a comparison with quantitative intracoronary ultrasound. Invest Radiol. 2008;43:314-321.
42. Strauss HW, Narula J. Atheroma roulette. J Nucl Cardiol. 2007;14:293-297.
43. Schafers KP, Stegger L. Combined imaging of molecular function and morphology with PET/CT and SPECT/CT: image fusion and motion correction. Basic Res Cardiol. 2008;103:191-199.
44. Nehmeh SA, Erdi YE. Respiratory motion in positron emission tomography/computed tomography: a review. Semin Nucl Med. 2008;38:167-176.
45. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48: 932-945.